Key Takeaways In a small trial, 8 of 16 patients responded well to the mRNA vaccineThe vaccine is personalized, based on each ...
The concept of using vaccines to treat cancers has been around for several decades. A vaccine was first approved for prostate cancer in 2010, and another was approved in 2015 for melanoma. Since then, ...
Fueled by pandemic frustrations, populist parties are embracing anti-vaccine figures — in the U.S. and elsewhere.
In a small trial, nearly half of pancreatic cancer patients who received an mRNA vaccine for the disease had no relapse three years later.
A Memorial Sloan Kettering phase 1 clinical trial revealed an immune response in some pancreatic cancer patients. Study ...
In trials, a vaccine for pancreatic cancer developed by Sloan-Ketterin and BioNTech showed promise, but researchers say it is ...
The phase 1 trial results, published Feb. 19 in Nature, evaluated the personalized mRNA neoantigen vaccine autogene cevumeran in combination with surgery, immunotherapy drug atezolizumab and ...
Healthy Savannah and the Chatham County Health Department are partnering to offer a cervical cancer awareness and screening ...
"GMA" examines a preliminary study where a personalized mRNA vaccine showed promise in reducing the risk of pancreatic cancer ...
Io Biotech Aps has presented preclinical data regarding their Arg1-derived peptide cancer vaccine IO-112 as a potential immunotherapeutic that would allow controlling the tumor microenvironment.
A personalized mRNA vaccine may reduce the risks of pancreatic cancer returning after surgery, according to a preliminary ...
Dr. Yuzhong Liu, an assistant chemistry professor at Scripps Research, was among three scientists granted $150,000 Wednesday ...